ABOUT US
YENO PIONEER IN FUNCTIONAL EPIGENETICS & INTEGRATIVE CELL REGULATION
YENO Awareness BV was founded in Amsterdam in 2014 and is the intellectual and conceptual parent company of the YENO Group. In 2020, it gave rise to YENO Evolution GmbH, based in Vienna, a specialized research and development company in the field of functional epigenetics. As a leader in functional epigenetics, YENO has achieved a technological breakthrough that heralds a new era in modern medicine.
YENO is now considered a leading innovator in this field, not because of its size or international structure, but because of its scientific innovation of extraordinary significance: the use of pure epigenetic signal transduction for the targeted regulation of cell functions.
This scientific breakthrough, developed over more than two decades of intensive research, represents a true revolution.
It creates unprecedented opportunities in regulatory and regenerative medicine, oncology, anti-aging medicine, and epigenetic rejuvenation. The patented “YENO Quantum ONE technology” (EU and USA) enables unique, scientifically proven access to the cell nucleus and precisely regulates key epigenetic positions. On this basis, epigenetic medicines (prescription medicines according to §21 AMG) and regulatory therapies have been developed, whose effectiveness has been confirmed by in vitro, in vivo, and observational studies.
THE TEAM & THE VISION
The core team at YENO, led by Claudia Bettina Klein and Hubertus Baumgartner, combines interdisciplinary knowledge and visionary implementation skills: technical and biophysical expertise meets strategic competence and entrepreneurial skill.
The joint ownership of the EU and US patent for the “GENOS method” underscores the company's ambition to play a key role in shaping integrative medicine, from cellular regulation to its application in practice and therapy. With the GENOS method, the various GENOS infusions, GENOS oral medication, and GENOS Fibrocell Rejuvenation Infusion, YENO not only covers the three most important future fields of medicine globally:
-
Epigenetic cell regulation
-
Cellular rejuvenation
-
Regenerative & integrative medicine, but also strives to expand the spectrum of integrative medicine with well-founded epigenetic, regenerative, and consciousness-promoting approaches.
OUR MANAGEMENT TEAM
Dipl.- Ing. Hubertus Baumgartner
CEO
MSc. D.I. Claudia Klein
CEO and Director R & D
Christoph Lauinger
Co-Founder
Prof. Dr. Hartmut Schröder
Ambassador
ADVISORY BOARD
Prof. Dr. Hartmut Schröder
Dr. Patrick Welter
Dr. med. Robert Trossel
HP Boris Dinjus
STAFF
Heike Schulz
Julia Klein
JOBS
OPEN VACANCY
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
OPEN VACANCY
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
OPEN VACANCY
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles. Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.